Table 1.

Baseline demographics and disease characteristics

Demographics (N = 91 patients)DLBCL (n = 47)iNHL (n = 31)MCL (n = 3)CLL (n = 10)
Median age (years)66.0 (30–89)64.0 (35–87)72.0 (50–73)72.5 (63–81)
Sex
 Female23 (48.9%)15 (48.4%)02 (20.0%)
 Male24 (51.1%)16 (51.6%)3 (100.0%)8 (80.0%)
ECOG performance status
 015 (31.9%)17 (54.8%)3 (30.0%)
 129 (61.7%)12 (38.7%)2 (66.7%)5 (50.0%)
 23 (6.4%)2 (6.5%)1 (33.3%)2 (20.0%)
Number of previous systemic therapies
 17 (14.9%)3 (9.7%)01 (10.0%)
 211 (23.4%)3 (9.7%)00
 ≥329 (61.7%)25 (80.6%)3 (100.0%)9 (90.0%)
Previous stem-cell transplantation5 (10.6%)5 (16.1%)00
Refractory to last therapya34 (82.9%)21 (77.8%)2 (100.0%)4 (57.1%)
Previous radiotherapy15 (31.9%)9 (29.0%)1 (33.3%)0
Previous rituximab therapy (at any timepoint)47 (100.0%)31 (100.0%)3 (100.0%)10 (100.0%)
  • NOTE: Data are median (range) or n (%).

  • aDefined as progression on or within six months of last dose of last previous therapy.